CSPC Pharmaceutical Group has released its 2026 AGM circular outlining several capital management and governance proposals. Key items will be voted on at the meeting scheduled for 28 May 2026 in Hong Kong.
Double-Mandate Requests • Buyback authority: Directors seek approval to repurchase up to 10% of issued shares (currently 1.15 billion shares) before the next AGM. All repurchased shares will be cancelled. • Issuance authority: A separate mandate would allow the Board to allot and issue new shares equivalent to 10% of existing share capital at a maximum 10% discount to the benchmark price. Directors will not seek to extend this mandate by adding repurchased shares.
Governance and Board Changes • Ten directors stand for re-election, including executive directors Dr Cai Lei and Mr Wei Qingjie and four independent non-executive directors. • Messrs Deloitte Touche Tohmatsu are recommended for re-appointment as external auditor; expected audit fee: RMB4.04 million–RMB5.47 million.
Corporate Framework Updates • Adoption of new Articles of Association reflecting Hong Kong’s treasury-share regime, paperless communication and hybrid/virtual meeting provisions. • Introduction of a new 10-year share option scheme to replace the 2015 plan (expired in December 2025). Key terms: — Scheme mandate limit: 10% of issued shares (1.15 billion). — Per-participant annual limit: 1% of issued shares. — Minimum vesting: 12 months, with limited exceptions. — Exercise price: no less than the higher of the closing price on the grant date or the average closing price for the five preceding trading days. — Claw-back provisions apply for misconduct or regulatory breaches.
Logistics • Shareholders must lodge transfer documents by 20 May 2026 to qualify for AGM attendance. • Register closure for dividend entitlement: 26–29 June 2026.
If approved, the new mandates and scheme will expand CSPC Pharmaceutical’s flexibility in capital management while imposing tighter safeguards against dilution and misconduct.
Comments